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Abstract
The field of interventional oncology with use of image-guided tumor ablation requires
standardization of terminology and reporting criteria to facilitate effective communication of ideas
and appropriate comparison between treatments that use different technologies, such as chemical
(ethanol or acetic acid) ablation, and thermal therapies, such as radiofrequency (RF), laser,
microwave, ultrasound, and cryoablation. This document provides a framework that will hopefully
facilitate the clearest communication between investigators and will provide the greatest flexibility
in comparison between the many new, exciting, and emerging technologies. An appropriate
vehicle for reporting the various aspects of image-guided ablation therapy, including classification
of therapies and procedure terms, appropriate descriptors of imaging guidance, and terminology to
define imaging and pathologic findings, are outlined. Methods for standardizing the reporting of
follow-up findings and complications and other important aspects that require attention when
reporting clinical results are addressed. It is the group’s intention that adherence to the
recommendations will facilitate achievement of the group’s main objective: improved precision
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and communication in this field that lead to more accurate comparison of technologies and results
and, ultimately, to improved patient outcomes. The intent of this standardization of terminology is
to provide an appropriate vehicle for reporting the various aspects of image-guided ablation
therapy.
Recently, the International Working Group on Image-Guided Tumor Ablation published a
document entitled “Image-guided Tumor Ablation: Proposal for Standardization of Terms
and Reporting Criteria” (1). The main objective was “improved precision and
communication in this field that leads to more accurate comparison of technologies and
results and ultimately to improved patient outcomes” (1). It was acknowledged by the
members of the working group that the new field of image-guided tumor ablation (a branch
of interventional oncology) required standardization of terminology and reporting criteria to
facilitate effective communication of ideas and appropriate comparison between treatments
that use different technologies. On the basis of this premise, a committee was established to
author proposed standards, with the proposal unanimously adopted by the committee and
ratified by the International Working Group on Image-Guided Tumor Ablation.
The initial goals of the working group’s proposal for standardization fall in line with the new
initiative of the Society of Interventional Radiology (SIR), which promotes interventional
oncology. Along these lines, a Technology Assessment Committee of the SIR has been
charged with reviewing and commenting on the standardization of terminology and
reporting criteria. Accordingly, the document has been modified in an attempt to align the
contents with prior SIR standards and to address additional issues that have been raised by
the Technology Assessment Committee. Additionally, we have attempted to respond to
several recommendations of the Food and Drug Administration’s Center for Devices and
Radiological Health in this version of the document. In essence, this independent review and
ratification by the SIR Technology Assessment Committee of the prior report (1) represents
a continuation of the collaborative initiative to consolidate and unite all investigators and
clinicians practicing interventional oncology by providing a common language to describe
therapies and outcomes.
CLASSIFICATION OF THERAPIES
Image-guided Tumor Ablation
The term tumor ablation is defined as the direct application of chemical or thermal
therapies to a specific focal tumor (or tumors) in an attempt to achieve eradication or
substantial tumor destruction (2– 6). The term “direct” aims to distinguish these therapies
from others that are applied orally or via an intravascular or peripheral venous route. We
stress the concept of image guidance in the title of our field to reflect our radiological
perspective and to highlight that image guidance is critical to the success of these therapies
(2– 6). Given that most of these therapies can be performed by using a host of imaging
modalities (ie, ultrasonography [US], computed tomography [CT], magnetic resonance
[MR] imaging, and fluoroscopy), the more general term image guidance is preferred, unless
a particular imaging modality is mandated as part of the technique. However, virtually all
available ablation techniques can theoretically be used with more than one modality.
While previously, some authors have referred to these procedures as “minimally invasive”
or “percutaneous” therapies, these terms should be used only where appropriate. Minimally
invasive therapies refer to all therapeutic procedures that are less invasive than conventional
open surgery. All percutaneous procedures are therefore minimally invasive; however, not
all minimally invasive therapies are performed or applied percutaneously. Indeed, the term
“minimally invasive” is often used by surgeons to refer to procedures performed with
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minilaparotomy or laparoscopy (7). Although less invasive than open surgery, these
procedures are clearly more invasive than are percutaneous image-guided tumor ablation
procedures. Inclusion of the term “percutaneous” as a prefix to “image-guided tumor
ablation” is often too limiting because it does not reflect the fact that tumor ablation
procedures can also be performed at laparoscopy, endoscopy, or surgery (8,9).
Individual procedures and therapies have often been given multiple different names by
various investigators, which can potentially lead to confusion. Hence, we propose and
recommend a unified approach to the terminology regarding these therapies. The primary
aim of this classification is to provide simplicity and clarity, most notably by eliminating
extraneous detail and many acronyms. The committee acknowledges that some acronyms
(such as RF and RFA for RF ablation and HIFU for high intensity focused ultrasound) have
gained widespread international acceptance. Nevertheless, niche application acronyms
should be avoided.
When discrimination between the ablation of malignant versus nonmalignant tissue is
needed, the descriptive term “ablation” should still be used, with the type of ablated tissue
stated afterward (eg, acetic acid ablation of renal cell carcinoma or RF ablation of
atherosclerotic plaque). In other words, the term “thermal (or laser, microwave, etc)
ablation” should be used regardless of what is being ablated.
The methods of tumor ablation most commonly used in current practice are divided into two
main categories: (a) chemical ablation and (b) thermal ablation. These categories require
further definition and standardization of terminology as outlined below. Other interventional
oncologic therapeutic approaches, including the percutaneous delivery of genetic material
and radioactive seeds and the transcatheter delivery of chemoembolization agents (10,11),
may ultimately require better definition but are beyond the scope of this current position
article. Nevertheless, many of the issues discussed concerning reporting criteria may likely
be equally appropriate for clinical trials with those therapies.
Chemical Ablation
These therapies are to be classified on the basis of the universally accepted chemical
nomenclature of the agent(s), such as ethanol and acetic acid, that induce coagulation
necrosis and cause tumor ablation (12–14). For example, the term “ethanol ablation” should
replace PEI (percutaneous ethanol instillation or injection), PAI (percutaneous alcohol
instillation), and others (12,13). When results are reported, the route (intravascular,
intraarterial, or interstitial), substances injected, delivery vehicle (size and type of needle or
catheter), and rate of delivery (rapid or bolus injection or a defined rate of infusion) should
be specified in the Materials and Methods section of the manuscript. The term “instillation”
for the direct delivery of pharmacologic agents is preferred, given that many pharmaceutical
agents can be injected (a process that implies rapid percutaneous delivery) or delivered
intravascularly with a catheter.
Thermal Ablation Procedures
This category includes energy sources that destroy a tumor by using thermal energy, with
either heat (eg, RF, laser) or cold (cryoablation) (15–45). For thermal therapies, energy is
“applied.” The term “irradiation of energy,” particularly in regard to microwave ablation, is
a misnomer and should therefore be avoided.
Procedure Terms
We prefer to use the term procedure rather than “operation,” as the latter implies open
surgery. We consider the term session to be synonymous with procedure. A procedure
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refers to a single intervention episode that consists of one or more ablations performed on
one or more tumors. Given that procedures may be repeated, a treatment consists of one or
more “procedures” or “sessions”; the term is used to define the completed effort to ablate
one or more tumors. Each manuscript should state clearly how many “procedures” or
“sessions” were needed and why.
Energy Sources and Applicators
Although the devices are often referred to as “needles” or other nonspecific terms, they do
not always conform to these precise classifications. Hence, the term applicator should be
used generally to describe all devices. For precision, RF applicators are electrodes,
microwave applicators are antennas, and laser applicators are fibers. On the basis of
convention and consensus, cryoprobes are used to freeze tissue during cryoablation. For
reporting completeness, a reference describing the appropriate applicator(s) should be cited
unless the report describes a new prototype device, in which case an appropriate figure and/
or schematic should be provided.
RF Ablation
This term applies to coagulation induction from all electromagnetic energy sources with
frequencies less than 30 MHz, although most currently available devices function in the 375
to 500 kHz range (15). The term “radiofrequency” should be written as a single
nonhyphenated word. Most devices currently used are monopolar in that there is a single
“active” electrode, with current dissipated at a return grounding pad. Bipolar devices have
two “active” electrode applicators, which are usually placed in proximity to achieve
contiguous coagulation between the two electrodes (16). Additionally, many electrode
modifications are now available, as classified below. The type of device and electrode used
clearly influences the extent of ablation. Hence, clarity and standardization of terminology
are required.
Multitined expandable electrodes—This standard term refers to a family of electrodes
that are currently available from several manufacturers (8,9, 17–20). The usual embodiment
of this type of device is an array of multiple electrode tines that expand from a single
centrally positioned larger needle cannula. Currently, these are referred to as “umbrella
electrodes,” “multi-tined electrodes,” “Christmas tree electrodes,” “multiple hooked
electrodes,” or “arrays,” but this has led to confusion. Given the number of electrode types
that have recently become available and the fact that several multitined devices are now
available with variable deployment lengths, the exact electrode model and diameter of the
electrode array used must be specified. Also, if a stepped deployment was performed with a
multitined device, this too needs to be explained in detail regarding the length and time of
deployment.
Internally cooled electrodes—Some devices have a perfusate (such as saline or water)
that flows in internal lumina that does not come in direct contact with patient tissues (21–
23). These should be referred to as “internally cooled” (single or cluster [not “clustered”])
and not confused with perfusion electrodes, as described below. The term cluster electrode
is most appropriate to describe internally cooled electrode devices in which three or more
closely spaced (<1 cm) electrodes are used simultaneously to approximate an electrode with
a larger diameter (24). Many investigators refer to these electrodes as “an array,” which may
not adequately reflect the true underlying mechanism for enhanced energy deposition and
ablation.
Perfusion electrodes—Electrodes that have small apertures at the active tip that allow
fluids (ie, normal or hypertonic saline [see “Adjuvant therapies” below]) to be infused or
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injected into the tissue before, during, or after the ablation procedure should be referred to as
perfusion electrodes (25,26). The term replaces descriptions such as “cool-wet,” “wet,” or
“saline-enhanced” electrodes.
Algorithm of energy deposition—The methods used for applying energy have
undergone continuous modification and improvement, which has led to substantial
confusion and difficulty when the results of studies performed by different groups of
investigators are compared. When reporting results, pulsing techniques and other methods
for amplifying energy deposition should be succinctly elaborated in the Materials and
Methods section. Whenever possible, a reference for the precise algorithm used (eg, ramped
energy deposition (18) or impedance regulated (27)) and the model number of the generator
should be cited. Additionally, other parameters, including the use of monopolar or bipolar
systems, the amount of energy applied (current [milliamperes] or power [watts]), and the
duration of ablation should be provided.
Adjuvant therapies—Increased use of adjuvant therapies, such as concomitant
percutaneous instillation of sodium chloride solutions to alter electric and thermal
conductivity during ablation, are being reported with many variations in technique (28,29).
Hence, specific details of the adjuvant used (ie, drug concentration, route and rate of
administration, timing in relation to ablation therapy) must be provided. Whenever possible,
a reference for the precise algorithm and the rationale for the selected adjuvant therapy used
should be provided.
Laser Ablation
The term laser ablation should replace terms such as “laser intersitital tumor therapy,”
“laser coagulation therapy,” and “laser interstitial photo-coagulation” (30–34). This term
should be used for all types of ablation with light energy. Given multiple laser technologies
and application methods, including superficial therapy (contact or noncontact mode) or
transcutaneous ablation, the term “interstitial” or “direct” can be reported to clarify that laser
energy is applied via fibers directly inserted into the tissue.
In addition to the laser source (eg, Nd:YAG, erbium, holmium) and precise wavelength,
additional device characteristics must be specified, including (a) type of laser fiber (flexible
or glass dome); (b) modifications to the tip (ie, flexible diffusor tip or scattering dome), with
dimensions and materials specified; (c) length of applicator and diameter of the optic fiber;
and (d) number of laser applicators used (ie, single vs. multiple applicators). Similar to the
reporting requirements for RF ablation, additional details of device modification, such as
pulsing algorithms and internal cooling of the applicator, should be provided. The following
technical parameters also should be provided: (a) laser power, reported as watts per
centimeter of active length of laser applicator; (b) total duration of energy application; (c)
total amount of energy applied per tumor (mean and range); and (d) sequential or
simultaneous energy application to multiple fibers. For energy applied, in addition to the
energy measured before the laser enters the fiber, ideally the actual energy output of the
fiber or dome prior to the ablation and/or at the end of the procedure should be measured.
Microwave Ablation
This term should be used for all electromagnetic methods of inducing tumor destruction by
using devices with frequencies from 30 MHz to 30 GHz (35–37). The term “microwave
ablation” should replace the less succinct terms “percutaneous microwave coagulation
therapy” and “microwave coagulation therapy.” Additionally, the precise frequency of the
device and the type of applicator(s) should be provided.
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Ultrasound Ablation
There are currently two methods for the application of ultrasound energy: extracorporeal (or
transcutaneous) (38) and direct for percutaneous application with a needle-like applicator
(39) and for intracavitary (and intracardiac) devices. Hence, the additional nomenclature of
“extracorporeal” or “direct” is required prior to focused ultrasound ablation. The term
“high intensity” (as commonly found in “high-intensity focused ultra-sound”) is not
essential because it is vague, imprecise, and implied by the proposed terminology.
Cryoablation
This term should be used to describe all methods of destroying tissue by means of the
application of low-temperature freezing (40 – 45). The term “cryotherapy” is a suitable
alternative because it has been used for many years to describe these methods, and it may
also be useful when a literature search on this subject is conducted (44). The phrase “cryo”
as a freestanding term is to be avoided because “cryo” is a prefix and not a word. The
archaic term “cryosurgery” is also to be avoided as imprecise, given the introduction of
newer applicators that can be introduced percutaneously in a minimally invasive fashion.
The freezing of tissue with rapid thawing leads to the disruption of cellular membranes and
induces cell death (45). In the past, liquid nitrogen was placed directly on tissue, but with the
exception of dermatologic applications, this method is no longer used. In the neck, chest,
abdomen, pelvis, and extremities, cryoablation is performed by using a closed cryoprobe
that is placed on or inside a tumor. In the two main types of systems, argon gas and either
gas or liquid nitrogen are used. Temperatures are measured either at the tip of the cryoprobe
or in the handle. In the past, temperature readings from cryoprobes have been a source of
controversy because some devices of manufacturers measure the temperature of the coolant
as it enters the distal probe tip and others measure at the probe tip itself. Hence, the
temperatures at which cryoablation is performed should be specified. For publication
purposes, the type of cryoablation system, the gases used, probe dimensions, and length and
number of freeze-thaw cycles (active or passive thawing) should also be specified.
Terminology for Describing the Effects of Blood Flow
All of the thermal methods are negatively influenced by blood flow because it can
potentially remove heat before complete tumor ablation is achieved (1– 6). (This is also true
in reverse for cryoablation, where the premature warming of tissue by blood can limit the
effects of freezing on tissue.) The term heat sink effect refers to cooling by adjacent visible
(>1-mm-diameter) blood vessels when ablated tissues are heated (46 – 48). In effect, the
shape of the thermal zone of ablation is altered away from the blood vessel, and the overall
ablation size is diminished due to removal of heat by flowing blood (46,47), or in the case of
cryoablation, due to addition of heat. Although these phenomena serve to protect blood
vessels and prevent bleeding from large vessels, they are also a major source of incomplete
tumor ablation in many studies involving both thermal and cryoablation. Perfusion-
mediated tissue cooling (or heating) is a more encompassing term that refers to both the
effects of the larger heat sink vessels and the substantial effects of capillary level
microperfusion (48). Several strategies have been developed to overcome this problem:
pharmacologically decreased blood flow (49), temporary vascular balloon occlusion of a
specific vessel during ablation (ie, hepatic artery, hepatic vein, and/or portal vein during
intrahepatic ablation) (50), intraarterial embolization and chemoembolization (36,51,52),
and a Pringle maneuver (ie, temporary hepatic arterial and portal venous occlusion by means
of direct compression of the vessels) during RF ablation at laparotomy (9,47).
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IMAGE GUIDANCE
While all procedures mentioned in this article refer to tumor ablations guided by imaging, it
is important to understand what is meant by the term “image guidance.” First, “guidance”
refers to procedures in which imaging techniques (eg, fluoroscopy, US, CT, and MR
imaging) are used during the procedure. Imaging is used in five separate and distinct ways:
planning, targeting, monitoring, controlling, and assessing treatment response (53).
Treatments are planned before the procedure, and the assessment of treatment response
occurs after the procedure is completed. Targeting, monitoring, and controlling are all
performed during the procedure.
Planning
Imaging techniques, including US, CT, MR imaging, and more recently positron emission
tomography (PET), are used to help determine whether patients are suitable candidates for
these procedures. Imaging aspects that are particularly important include tumor size and
shape, number, and location within the organ relative to blood vessels, as well as critical
structures that might be at risk for injury during an ablative procedure. Modalities such as
combined PET and CT and three-dimensional reconstructions of cross-sectional imaging
data may be used more often in the planning of image-guided tumor ablations in the future.
Targeting
This term is used to describe the step during an ablation procedure that involves placement
of an applicator (eg, an RF electrode or cryoprobe) into the tumor. While much of the
current image-guided tumor ablation literature describes the use of techniques such as US
and CTto target tumors for purposes of ablating them, targeting is only one aspect of
intraprocedural image guidance. Ideal qualities of a targeting technique include clear
delineation of the tumor(s) and the surrounding anatomy, coupled with real-time imaging
and multiplanar and interactive capabilities. For example, US (54) and some MR imaging
(55,56) systems have all of these qualities.
Monitoring
Monitoring is the term that is used to describe the process with which therapy effects are
viewed during a procedure. Changes in imaging that occur during a procedure can and
should be used to determine treatment effects. Important aspects of monitoring include how
well the tumor and/or target is being covered (ie, included and/or encompassed) by the
ablation zone and whether any adjacent normal structures are being affected at the same
time. Not all image-guided techniques provide the same degree and types of monitoring. For
example, MR imaging is currently the only modality with well-validated techniques for real-
time temperature monitoring (40,57–59). The term “monitoring” should not be used to
describe response to treatment; for this, “treatment assessment” or “follow-up” is used.
Controlling
This term is used to describe the intraprocedural tools and techniques that are used to control
the treatment. To control an image-guided ablation procedure, the treatment should be
monitorable, such that the operator can utilize the image-based information obtained during
monitoring to control it. This may simply be repositioning of a therapy applicator on the
basis of physician experience, imaging findings, and thermal feedback, or it could be as
sophisticated as an automated system that automatically terminates the ablation at a critical
point in the procedure (60).
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Assessment of Treatment Response
Imaging used to assess an image-guided tumor ablation procedure occurs after the procedure
is completed and is discussed below as postprocedural imaging (2– 6).
PATHOLOGIC AND IMAGING FINDINGS
The difference between pathologic findings and imaging findings must be stressed by the
appropriate selection of terminology. Although in many cases there is a good correlation or
overlap between radiological and pathologic findings, this is not invariably the case since
over- and under-reporting of the true extent of disease has occurred (61,62). The classic
example of this is the assumption that imaging findings (ie, the zone of abnormality on the
image) are equivalent to the pathologic findings (ie, the true zone of tumor destruction and/
or treatment effect), which may not always be the case. Hence, careful differentiation
between imaging and pathologic findings must be made. This distinction is critical, given
that the accuracy of assessment of the extent of tumor destruction by means of imaging
findings is limited by the resolution of images and the uncertainty about the viability of cells
at the radiographic margins of the zone of ablation.
Zone of Cell Death at Pathologic Examination
This should be referred to as coagulation or coagulation necrosis. Given that many tumors
undergo central necrosis without ablation therapy, the term “coagulation” is preferred over
the use of “necrosis” alone because it denotes that the ablation intervention is actively
leading to tumor destruction. The more generalized term “coagulation” is preferred over the
term “coagulative necrosis” because the latter term has a well-defined meaning in the
pathology literature, including the absence of visible nuclei within the dead cells. In
actuality, the zone of coagulation, while predominantly consisting of coagulative necrosis,
often lacks the classic well-defined histologic appearance of coagulative necrosis in the
acute postablation period or even within some zones of adequately ablated tissue for many
months following ablation (22,61,63). Indeed, in many cases, specialized stains are required
to confirm that cellular death has been achieved after thermal ablation (61).
Another important issue is definition of the zone of ablation at gross pathologic
examination. Most thermal therapies induce a central “white zone” of coagulation, a
pathologic finding that is generally accepted to represent coagulated tissue, surrounded by a
variable “red zone” of hyperemia that is most often absent in ex vivo specimens (64).
However, there has been controversy in the measurement; hence, comparison of the “true”
size of induced zones of ablation is based on the fact that some authors have reported that
this more peripheral red zone also represents ablated tissue, and they include it in their
measurements. To avoid confusion, both measurements (white zone alone and white plus
red zones) should be provided. At a minimum, the zones included in gross pathologic
measurements should be specified.
Zone of Ablation at Postprocedural Imaging
Appropriate terminology must reflect the fact that although we rely on imaging to define the
gross extent of induced coagulation, our accuracy is limited by both spatial and contrast
resolution to approximately 2 to 3 mm (depending on the imaging modality) (61). Hence, in
truth, postprocedural imaging findings are only a rough guide to the success of ablation
therapy, since microscopic foci of residual disease, by definition, cannot be expected to be
identified. The term “ablation zone” can be used to describe the radiological region or zone
of induced treatment effect (ie, the area of gross tumor destruction visualized at imaging).
The term “lesion” is to be avoided, given the potential confusion about the intended
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meaning, since the term “lesion” has been used to refer to both the “ablation zone” and the
underlying tumor to be ablated.
There are two types of imaging findings that are identified after an ablation procedure: those
related to zones of decreased perfusion and those in which the signal intensity (at MR
imaging), echogenicity (at US), or attenuation (at CT) are altered (1– 6). Hence, the imaging
strategy and the criteria used to define ablation must be specified. For contrast material–
enhanced studies, it is important to recognize that in some organ sites, particularly the
kidney, minimal contrast enhancement (ie, < 20 HU for CT) seen soon after ablation can be
identified in areas that are subsequently proved at pathologic examination to be uniformly
dead tissue (65). (This finding is not well understood but may be due to
pseudoenhancement, as has recently been described for renal cysts, or to represent true
minimal enhancement from leaky capillaries at the treatment margin.) Other imaging
findings also require precise definition.
Transient hyperechoic zone—This is the preferred term to describe the transient (up to
30 –90 min) zone of increased echogenicity seen at US within and surrounding a tumor
during and immediately after RF ablation (66,67). Thereafter, treated tumors often develop
mixed echogenicity on follow-up scans. This finding is believed to represent microbubbles
of water vapor and other cellular products that form as a result of tissue vaporization during
active heating and is most often used as a rough guide as to the extent of induced tumor
destruction. However, it is not a precise marker, because both under- and overestimation of
the true extent of coagulation have been reported. The term “transient hyperechoic zone”
should replace imprecise terms such as “ultrasound cloud,” “ultrasound storm,” “outgas-
sing,” and “microbubble vaporization.”
Ablative margin—For many disease processes, particularly for tumors in the liver, the
ablation of appropriate margins beyond the borders of the tumor is necessary to achieve
complete tumor destruction. The term “ablative margin” is proposed to describe the 0.5 to
1.0-cm-wide region that should ideally be ablated in these cases (68). This term is preferable
to “surgical margin” (because there is no surgery). It is important to stress that this extent of
treatment is not always necessary or desired, particularly during attempts to destroy focal
tumors in the kidney in patients with a tendency toward the development of multiple tumors
(such as those with von HippelLindau disease), where nephron-sparing and more limited
ablation are desired to preserve renal function and avoid dialysis (65).
For normally vascular organs such as the kidney and liver, creation of an ablative margin
results in zones of low attenuation and absent perfusion that extend into the parenchyma (2–
6). Increased attenuation occurs in low-density tissues such as perinephric fat (for exophytic
renal tumors) (65,69) and the lungs, where the term “ground-glass opacity” is used to
describe the imaging findings in the treatment zone surrounding and including the ablated
lung tumor (70).
Benign periablational enhancement—This finding can be seen at both pathologic
examination and contrast-enhanced imaging and typically suggests a benign physiologic
response to thermal injury (initially, reactive hyperemia; subsequently, fibrosis and giant cell
reaction) (61). Depending on the protocol used for contrast-enhanced imaging (injection rate
and scanning delay), this transient finding can be seen immediately after ablation and can
last for up to 6 months after ablation. This finding usually manifests as a penumbra, or a thin
rim peripheral to the zone of ablation, that can typically measure up to 5 mm acutely but
most often measures 1 to 2 mm. It is a relatively concentric, symmetric, and uniform process
with smooth inner margins, and it needs to be differentiated from “irregular peripheral
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enhancement.” The finding is most readily appreciated on the arterial phase CT scans, with
persistent enhancement that is often seen on delayed MR images.
Irregular peripheral enhancement—This term represents residual tumor that occurs at
the treatment margin. In contrast to “benign periablational enhancement,” residual unablated
tumor often grows in scattered, nodular, or eccentric pattern. This sign indicates incomplete
local treatment (ie, residual unablated tumor). As such, if they are not subject to further
therapy, these foci tend to continue to grow. Given the delayed enhancement characteristics
of many hypovascular tumors, this finding is often best appreciated in a comparison of
portal venous or delayed images (3 or more minutes after contrast material injection) with
baseline images.
Involution of coagulation—The term “involution” should describe the process by which
the body eliminates the zone of induced coagulation over time. The term “shrinkage” should
be avoided as imprecise. The term “regression” is likewise to be avoided, given that it is
commonly used in the medical oncology literature to describe involution of just the tumor
itself, rather than the induced coagulation that often involves both the tumor and the
surrounding tissues (ie, the ablative margin). It is important to note that no or minimal
involution does not imply treatment failure.
Other imaging findings—Many other imaging findings that represent both host reaction
to ablation and repair mechanisms will undoubtedly be seen and reported. Such findings
include inflammatory stranding in the acute period after ablation and more chronic findings,
such as fibrosis, scarring, and architectural distortion. In general, despite the tendency
toward creative description, previously standardized radiological nomenclature should be
used to describe these findings whenever possible. The number of new terms to describe
these processes should be minimized to wherever new descriptive terminology imparts
prognostic value (eg, differentiating between benign peri-tumoral enhancement and residual
unablated tumor).
Reporting of Tumor and Ablation Sizes
Appropriate uniform guidelines and standards are needed to report the extent of induced
coagulation. In the past, comparisons between technologies have been made somewhat
difficult because some authors report the largest diameter of induced coagulation, some
report the average diameter, and some report the short-axis diameter. Additionally,
coagulation has occasionally been reported as a volume of ablated tissue without any
definition of dimensional measurements. Hence, uniform standards of comparison are
essential and must be adopted.
Index tumor—This is the preferred term to describe the initially identified tumor prior to
ablation. This tumor should not be referred to as a “lesion” because this term could be
confused with the zone of induced coagulation or the region of ablation at imaging.
Size classification of tumors—Actual tumor sizes (mean ± SD and range if applicable)
should be reported. Given that appropriate ablation of adequate margins often represents the
rate-limiting step for treatment effectiveness, the maximum diameter of the original tumor
must be specified. However, many investigators perform analyses of their results on the
basis of stratification of tumor sizes. In this regard, there is currently too much ambiguity
and variability in the categorization of tumors by size. Investigators have reported upper
limits of 2.0, 2.5, 3.0, and 5.0 cm in diameter for “small tumors” and 5 or 10 cm for “large
tumors.” These differences have made the direct comparison of results with different
technologies challenging. We, therefore, recommend that if such categorization is
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performed, the tumor size classification should be standardized according to the following
scale: small tumors, diameter of 3 cm or less; intermediate tumors, diameter of 3 to 5 cm;
and large tumors, diameter of more than 5 cm. This classification was determined as the
most practical because it parallels the current technical capabilities and effectiveness for
most image-guided ablation therapies.
Comparing zones of coagulation among different ablation techniques—Often,
the extent of induced coagulation is reported in experimental studies as a vehicle for
comparing different ablation technologies and parameter modifications (71,72). The extent
of induced coagulation should include the short-axis diameter, given that this parameter
influences the overall extent of necrosis that can be achieved from a single application of
energy and is likely to be an important factor that influences technical success in clinical
practice. Hence, while additional parameters can certainly be provided and may be
potentially useful, at a minimum this should be the standard that is reported to enable honest
comparison between techniques. Of course, given that the ablation of a tumor is performed
in three dimensions (ie, it is a volumetric problem), ideally, all three-dimensional
measurements of the ablation zone and tumor should be provided, and less ideally, both
measurements of the cross-sectional area should be provided. If volume is to be used as the
only reported parameter, then a rationale must be specified. Average diameters should be
accepted only if the tumor or zone of ablation is truly spherical, varying not more than 2 to 3
mm in cross-sectional diameter. It is further well known that many devices produce
irregularly shaped zones of coagulation. Hence, the degree of uniformity or irregularity in
the shape of the ablation zone should be specified.
It is important to stress that reliance on minimum and maximum sizes for the zone of
ablation may not be useful for predicting clinical technical effectiveness because other
technical factors are likely to be equally important. For instance, depending on the
orientation of the energy applicator, a 1 × 2-cm tumor may be adequately treated with a 2 ×
3-cm zone of ablation but not with a 3 × 2-cm zone of ablation. Ablation diameter or volume
may also not tell the entire story. Although a 3 × 3-cm zone of coagulation may completely
cover a 2-cm-diameter tumor when it is correctly positioned; if the zone is off the mark, the
entire tumor will not be destroyed.
STANDARDIZATION OF FOLLOW-UP
Currently, definitions of the appropriate length of follow-up and the time points for technical
success are not well established. One investigator’s long-term follow-up is often another’s
short-term follow-up. Hence, specific guidelines need to be adhered to that depend on the
type of disease treated and the intended goal of the study. Treatment study goals are
generally related to one or more of the following four categories, which usually need to be
distinguished from each another: (a) technical success, or, was the tumor treated according
to the protocol? (b) technique effectiveness, or, was the tumor effectively ablated? (c)
morbidity, or, were critical structures and complications avoided? and (d) outcomes, or, was
there some improvement in survival, quality of life, or palliation?
Technical Success
This term simply addresses whether the tumor was treated according to protocol and was
covered completely. Tumor coverage can be assessed either during or immediately after the
procedure. For example, MR imaging can be performed to monitor thermal injury and to
show that the tumor is being covered completely during the procedure. Contrast-enhanced
CT can be performed immediately after ablation. A tumor that is treated according to
protocol and covered completely, as determined at the time of the procedure, is “technically
successful.” The importance of this term is to help investigators separate those patients in
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whom the protocol could not be executed completely, for either technical reasons or reasons
related to comorbid disease, from those that were treated according to protocol.
Technique Effectiveness
Distinction between “technical success” and “technique effectiveness” must be made.
Effectiveness can only be demonstrated with appropriate clinical follow-up. “Technique
effectiveness” should therefore refer to a prospectively defined time point (ie, immediately
after the last course of a defined ablation protocol or at 1 wk or 1 mo after treatment), at
which point “complete ablation” of macroscopic tumor as evidenced at imaging follow-up
(or another specified end point) was achieved. The number of sessions (ie, the number of
interventional procedures) to achieve the specified end point should likewise be defined.
Authors are encouraged to report whether or not this complete ablation included an ablative
margin.
Comparison of technical success and effectiveness between various ablation protocols has
been challenging because many authors have adopted different terminology or guidelines.
This problem is further compounded by our ability, and often the clinical need, to ablate a
tumor over many sessions and the possibility of ablating growing foci of local tumor
progression months after the initial course of therapy. A window of initial therapy for each
ablation technique, during which it is reasonably expected that the tumor will be completely
ablated, should be defined. For percutaneous thermal ablation, this window should ideally
not exceed an upper limit of either one to four procedures or a specified time frame (up to 1–
3 mo), depending on the size, type, and location of the tumor, as well as the rationale for
therapy. We have purposefully left definition of this end point as a broad range, given
evolving consensus on defining more specific parameters because each disease process may
vary. If complete ablation cannot be achieved within these specified parameters, the tumor
should be classified as “unsuccessfully treated.”
Primary and Secondary Technique Effectiveness Rates
Given that multiple treatments with image-guided tumor ablation therapy are often given
over the course of the disease, primary and secondary technique effectiveness rates should
be reported. The primary effectiveness rate is defined as the percentage of tumors that
were successfully eradicated following the initial procedure or a defined course of treatment.
The secondary or assisted effectiveness rate includes tumors that have undergone
successful repeat ablation following identification of local tumor progression. The term re-
treatment should be reserved for describing ablation of locally progressive tumor in cases
where complete ablation was initially thought to have been achieved on the basis of imaging
findings that demonstrated “adequate” ablation of the tumor.
The technical success and technique effectiveness rates are very important as we define the
limitations of our technologies, ideally in a manner similar to that used in other disciplines
(ie, articles about surgical resection typically report a positive margin rate). Nevertheless, for
some protocols, the concepts of local technical success and local tumor progression (ie,
technique effectiveness) may have limited impact on the most important outcome parameter:
patient survival. For example, use of three to four procedures or 1 month as the window of
technique effectiveness may be of secondary importance if the patient lives for 5 years
because of the treatment or if the tumor is completely eradicated over multiple courses of
ablation therapy over many years.
Complete Ablation versus Partial Ablation
Many reports have surfaced in which different degrees of partial ablation have been reported
(22,30,33, 73,74). While consensus has been achieved for defining complete and incomplete
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ablation, there has been a rather arbitrary definition of incomplete ablation. For example,
some authors have reported nearly complete ablation as representing greater than 90%
induced necrosis, while others have used a threshold of 95% necrosis of the index tumor.
Nevertheless, it is the opinion of the majority of the committee that this kind of
classification of partial ablation is not warranted in an overwhelming majority of cases,
given that adequate data are lacking to support a difference in outcome between different
levels of partial ablation. Furthermore, such percentages are often estimates and may be
inaccurate. Hence, at this time, such stratification should be avoided. It is important to stress
that the elimination of this type of stratification does not negate the utility or imply the lack
of benefit of tumor ablation as a palliative method. However, other end points should be
chosen (see below) when reporting these cases on the basis of the rationale of palliation.
Tumor Palliation
The specified well-defined rationale for palliative therapy, as well as an appropriate method
for assessing outcomes, must be provided. For example, if tumor ablation is valid as a
vehicle for pain reduction, pre- and postprocedural pain scales should be obtained (75,76). If
ablation is performed to reduce symptoms of a syndrome (such as carcinoid or other
hormonally active or paraneoplastic tumors (77)), appropriate documentation of laboratory
results from blood or urine obtained before and after therapy must be provided, and other
symptom end points and grading systems must be specified and used. Needless to say, one
cannot “palliate” asymptomatic tumors. Hence, the term debulking should be used to
describe a procedure performed with the sole intent of inducing a reduction of tumor burden.
Failure of Therapy
Causes of treatment failure—The distinction between local incomplete therapy (tumor
progression), new foci of disease in the target organ (especially the liver), and distant
malignancy should be distinguished whenever possible and reported. Discrimination
between “local tumor progression” and new tumor is important for determining the potential
utility (ie, local treatment success rate) of a given method in the setting of many potentially
confounding causes of the death of a given patient. Additionally, for patients with cirrhosis,
the causes of mortality should be differentiated between hepatic disease and others.
Local tumor progression—Many authors have used the term “local recurrence” to
describe the appearance over follow-up of foci of untreated disease in tumors that were
previously considered to be completely ablated. This is often a misnomer, given the fact that
the tumor in essence did not recur but instead was never completely treated. Hence, the
process often described is actually “residual unablated tumor.” However, in many cases, it is
virtually impossible to determine whether there was incompletely treated viable tumor that
continued to grow or if a new tumor (or in the case of hepatocellular carcinoma, “daughter”
or “satellite” tumors) grew at the original site. Given this reality, local tumor progression is
the preferred term over “local recurrence.”
Patient Mortality
Given that the population of patients that is treated most often are those with cancer,
substantial patient mortality that is unrelated to the ablation intervention is anticipated,
particularly in clinical studies with long-term follow-up. Therefore, the cause of death
should be specified as “tumor related” or due to “other causes.” For tumor-related death,
further subclassification (eg, differentiating death due to hepatic or diffuse metastatic
burden), if possible, will often be useful because it can potentially shed further light on the
effectiveness of therapy.
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COMPLICATIONS
The unified standardized SIR grading system should be used as outlined here (78,79).
Complications should be reported by using the SIR standard table so that they can be
categorized consistently according to severity. The definition of death is self-explanatory
and should be reported on a per-patient basis. Any patient death within 30 days of image-
guided tumor ablation should be addressed (SIR classification F). The specific cause of
death should be reported, with the potential and degree of causality to the ablation procedure
clearly specified. Major and minor complications and side effects should be reported on the
basis of the number of ablation sessions on a per-session basis. However, ideally, the
number of ablations performed should be included because multiple ablations increase the
likelihood of complications (80,81).
The definition of major complication is an event that leads to substantial morbidity and
disability, increasing the level of care, or results in hospital admission or substantially
lengthened hospital stay (SIR classifications C-E). This includes any case in which a blood
transfusion or interventional drainage procedure is required. All other complications are
considered minor. It is important to stress that several complications, such as pneumothorax
or tumor seeding, can be either a major or minor complications, depending on severity. For
tumor seeding, this would depend on whether the ectopic tumor focus can be successfully
ablated or otherwise treated.
Differentiation between immediate complications (up to 6 –24 h following the procedure),
periprocedural complications (within 30 d), and delayed complications (more than 30 d after
ablation) is advised. This stratification will give the reader an idea of when specific
complications or side effects are most likely to occur and assist in defining when and how to
take adequate precautions. Ablation-related complications should include problems
encountered within the periprocedural (30 d) time period that can be related in any way to
the procedure, as well as additional complications identified at delayed follow-up imaging
that were judged to be highly likely due to the ablation therapy (eg, biliary ductal stricture,
tumor seeding along the needle tract). Additionally, it should be specified which
complications are being reported on a patient-by-patient basis (such as death) and whether
the denominator represents the number of sessions or the number of tumors.
Side Effects
Side effects are expected undesired consequences of the procedure that, although occurring
frequently, rarely if ever result in substantial morbidity. These include pain, the postablation
syndrome, asymptomatic pleural effusions, and minimal asymptomatic perihepatic (or renal)
fluid or blood collections seen at imaging. Another such side effect would include
asymptomatic imaging evidence of minimal thermal damage to adjacent structures without
other evidence of negative sequelae (ie, “collateral damage”). An example of this would
include when the zone of ablation extends beyond the liver capsule to include small portions
of the diaphragm or kidney. These are not true complications because they do not lead to an
unexpected increased level of care.
Pain
Even with appropriate conscious sedation techniques, patients may experience pain during
ablation procedures. Additionally, depending on the organ site, many patients may
experience grade 1 to 2 pain for several days, occasionally lasting 1 to 2 weeks following an
ablation procedure. Last, thermal ablation, particularly RF, is being used with increased
frequency as a method for treating refractory metastatic and primary bone tumor pain
(75,76). We, therefore, propose adoption of the Common Toxicity Criteria of the National
Goldberg et al. Page 14
Radiology. Author manuscript; available in PMC 2012 July 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Cancer Institute for reporting pain (this document can be downloaded from the Web site
ctep.cancer.gov/reporting/ctc.html) (82): grade 0, no pain; grade 1, mild pain that does not
interfere with function; grade 2, moderate pain or pain or analgesics that interfere with
function but not interfere with activities of daily living; grade 3, severe pain or pain or
analgesics that severely interfere with activities of daily living; and grade 4, disabling pain.
Postablation Syndrome
This syndrome is a transient self-limiting symptom or sign complex of low-grade fever and
general malaise (44,83). The duration depends on the volume of necrosis produced and the
overall condition of the patient. If small areas are treated, the patient is unlikely to
experience postablation syndrome at all. If very large areas of liver tumors are ablated, the
syndrome may persist for 2 to 3 weeks. The majority of patients who have this syndrome
will experience some malaise for 2 to 7 days depending on the volume of tumor and
surrounding tissue ablated and the integrity of the patient’s immune system (ie, patients
being treated with steroids or those who have small tumors may experience postablation
syndrome).
Follow-up and Outcomes
Outcomes of interest may include local response, systemic response (pain, cancer
syndromes, etc), quality of life, or survival. For those studies that deal with the quality of
life, some form of objective measurement must be used both before and after treatment.
Ideally, previously validated scales or metrics should be used and appropriately referenced.
Imaging follow-up—Currently, despite a reliance on imaging findings to determine the
extent of “unablated residual tumor,” there is a lack of consensus on a standard follow-up
interval regimen for imaging. The most common approach taken by members of the
Working Group includes contrast-enhanced CT or MR imaging within 6 weeks of the initial
ablation to determine whether additional ablation therapy is required (many centers perform
this examination on the day of the initial procedure) and thereafter every 3 to 4 months to
determine technique effectiveness. Imaging intervals may also vary depending on the type of
underlying tumor and the goals of treatment. At a minimum, the intervals at which follow-
up imaging was performed should be clearly specified.
Although standard imaging criteria for response assessments have been defined for
evaluation of other cancer therapies, these criteria focus almost exclusively on tumor size
(84). However, given the heavy reliance on morphologic features other than size in the
assessment of results of ablation therapy, exclusive reliance on tumor size does not provide a
complete imaging assessment of tumor response and may even lead to erroneous
conclusions about the effectiveness of the therapy (85). Therefore, in addition to reporting
index tumor and the zone of ablation diameters, assessment of tumor enhancement or lack
thereof should also be included in the imaging response assessment following ablation
therapy.
Length of follow-up—Currently, many, if not most, published studies for most tumor
ablation technologies are preliminary and include only a limited number of patients, with
longer periods of follow-up. However, ideally, we will need studies in which large numbers
of patients are followed up. When survival and disease-free survival are assessed, an
appropriate length of follow-up should be selected on the basis of tumor biology and
accepted criteria for other therapies for a given tumor type. For example, the surgery
literature has required long-term follow-up of more than 5 years for determining the effect
of various therapies on survival for colorectal metastases to the liver or hepatomas (86 – 88).
For other tumors, the appropriate length of follow-up may vary and, indeed for more rapidly
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growing tumors, such as those in the lung, the length of follow-up may be shorter. For slow-
growing tumors, such as primary renal cell carcinoma, the length of follow-up may need to
be longer. As a general rule, we advocate the rapid establishment of a consensus on
acceptable follow-up times for different tumors. Regardless, on the basis of these concerns,
we recommend reporting of the actual mean and/or median length of follow-up (with ranges
and/or standard deviations, as appropriate) rather than arbitrary classification into short,
intermediate, or long.
OTHER IMPORTANT ASPECTS REQUIRING ATTENTION WHEN
REPORTING CLINICAL RESULTS
Technique Parameters to Be Provided for Publication
It is our belief that many published series do not provide enough technical detail to permit
duplication of the investigators’ efforts. This problem is compounded by the fact that there
are many different types of ablation equipment on the market and in development and these
often change. Hence, the specification of the parameters such as duration of energy applied
and manufacturer must be provided. Also, the number of treatment sessions for each tumor
should be specified. The procedure approach (ie, whether the procedure was performed
percutaneously, laparoscopically, or endoscopically) should also be clearly specified.
Additional parameters to be provided for publication should include the following: (a)
whether the procedure is performed with general anesthesia or conscious sedation (the
specifics of anesthetics and medications administered during the procedure and in the
recovery phase should be always reported, including agent, dose, and route), (b) the types of
imaging guidance (CT, CT fluoroscopy, US, MR imaging), (c) whether the patient was
hospitalized, (d) the number of sessions required to initially achieve technical success, and
(e) the subsequent rates of other tumors requiring additional ablation therapy. Last, any
repositioning of the applicator during the ablation and the procedure for applicator removal
(ie, use of fiber enclosure or other closure devices) should be noted.
Other Study Population Data to Be Reported
The study population should be rigorously described, including inclusion and exclusion
criteria and tumor type and size. The degree of proof of disease required for entry into the
study (ie, biopsy, imaging, or serologic criteria) should be clearly specified. Pretreatment
evaluation also needs to be reported. In addition to an appropriate focus on anatomy (ie, the
organ, tumor size, location, and number), the pretreatment evaluation should also include
tumor stage (ie, spread elsewhere), patient comorbidities, age, sex, and overall clinical
debility, because outcomes such as mortality will depend on these factors. Obviously, a
debilitated cachectic patient with widespread metastases will have a worse outcome
following liver RF ablation than will an otherwise well patient.
Findings of a recent study (89) have also suggested the potential complementary effects of
chemotherapy and radiation therapy on ablation effectiveness. Hence, the administration of
either of these therapies to patients enrolled in clinical trials of ablation should be specified.
This should be further classified as having received the conventional oncologic therapies
previously, around the time of ablation (within 1 mo) or during the follow-up period. The
specific therapy protocol and the duration of therapy in relation to the ablation therapy
should also be provided.
Accurate and Complete Delineation of Ablation Procedures
Substantial confusion and difficulty in comparing results have arisen regarding the success
and complication rates because patients may have had one or more tumors treated over
multiple procedure sessions. Ideally, all four parameters (numbers of patients, tumors,
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treatment sessions, and ablation procedures) should be reported whenever possible.
Additionally, results are often reported for heterogeneous populations of patients for which
varied rationales for the procedure (cure vs. palliation) or outcomes (hepatic metastases vs.
hepatocellular carcinoma) have been reported. Therefore, stratification of patients into
appropriate categories is advised to avoid confusion and best facilitate extraction of
clinically meaningful conclusions.
Minimizing Technical Jargon
Although substantial technical jargon and marketing terminology appear in the peer-
reviewed medical literature, these should not be used. For example, colloquial phrasing such
as “lesioning” and “burning” are to be avoided when describing the application of thermal
energy. Another example is the concept of “roll off” to describe the impedance control
algorithm of a device of one particular manufacturer; this term should not be used.
Comparison to Other Treatments
Given that most reports of image-guided therapy have been relatively small case series, a
major benefit of uniform reporting standards is the ability to perform meta-analyses of
outcomes to compare therapies (90). Clinical research studies should be reported in such a
manner that the results can be directly compared to various cancer therapies, including other
forms of image-guided ablation, surgery, radiation therapy, and chemotherapy. The coin of
the realm in oncology is survival, disease-free survival, and quality of life stratified
according to disease stage and patient functional status (91,92). Nevertheless, there are
limited data addressing these issues for most diseases treated with image-guided ablation
(93). Thus, the committee wishes to stress the need for studies on organ-by-organ and
disease-by-disease bases. Randomized, controlled, and blinded studies are considered the
standard for pivotal studies and should be performed when possible (94 –97). By the same
token, the committee acknowledges both the very real obstacles to performing such studies,
(patient recruitment, long periods of data collection, expense, multicenter organization, etc)
and the benefit of reporting less robust forms of data, including retrospective studies, case
series, and case reports (94,98).
Statistical Evaluation
Regardless of the study type, rigorous statistical evaluation appropriate for the data collected
should be presented (95,97). The primary and secondary study end points should be clearly
stated. By bearing in mind that the data from individual studies may need to be treated
differently, in general survival outcomes should be reported by using life-table (Kaplan-
Meier) analysis. Patients should be randomized, if possible, and results should be reported
on the basis of the intention to treat, whether patients were treated as randomized and
whether they were treated per protocol (ie, excluding protocol violations). Outcomes may
further need to be stratified according to multiple factors (tumor type, grade, and stage;
functional status; comorbidities; etc). Appropriate methods for assessment of quality of life
should likewise be selected (99).
CONCLUSIONS
The intent of this proposal for standardization of terminology is to provide an appropriate
vehicle for reporting the various aspects of image-guided ablation therapy. Our intent is to
provide such a framework to facilitate the clearest communication between investigators and
the greatest flexibility in comparison between the many new, exciting, and emerging
technologies. Clearly, this is an ongoing process that will require modification as our
understanding of these technologies improves, new treatment paradigms emerge, and greater
consensus is achieved on standardizing the reporting of currently unresolved issues. Indeed,
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we welcome constructive feedback from the medical community at large in an attempt to
further refine this proposal. Nevertheless, we encourage all of our colleagues to adopt the
terminology and reporting strategies outlined in this proposal.
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